Treatment of neovascular age-related macular degeneration: Current therapies

Albert J Augustin, Stefan Scholl, Janna KirchhofDepartment of Ophthalmology, Klinikum Karlsruhe, GermanyAbstract: Choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD) is now the leading cause of blindness and severe vision loss among people over the age of 40 in the...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Albert J Augustin, Stefan Scholl, Janna Kirchhof
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2009
Materias:	Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/30772ebc671d418aaa9808f2565196a1
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:30772ebc671d418aaa9808f2565196a1
record_format	dspace
spelling	oai:doaj.org-article:30772ebc671d418aaa9808f2565196a12021-12-02T02:18:41ZTreatment of neovascular age-related macular degeneration: Current therapies1177-54671177-5483https://doaj.org/article/30772ebc671d418aaa9808f2565196a12009-01-01T00:00:00Zhttp://www.dovepress.com/treatment-of-neovascular-age-related-macular-degeneration-current-ther-a2776https://doaj.org/toc/1177-5467https://doaj.org/toc/1177-5483Albert J Augustin, Stefan Scholl, Janna KirchhofDepartment of Ophthalmology, Klinikum Karlsruhe, GermanyAbstract: Choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD) is now the leading cause of blindness and severe vision loss among people over the age of 40 in the Western world. Its prevalence is certain to increase substantially as the population ages. Treatments currently available for the disease include laser photocoagulation, verteporfin photodynamic therapy, and intravitreal injections of corticosteroids and anti-angiogenic agents. Many studies have reported the benefits of each of these treatments, although none is without its risks. No intervention actually cures AMD, nor the neovascularization associated with it. However, its symptoms are treated with varying degrees of success. Some treatments stabilize or arrest the progress of the disease. Others have been shown to reverse some of the damage that has already been done. These treatments can even lead to visual improvement. This paper will review the major classes of drugs and therapies designed to treat this condition.Keywords: wet AMD, neovascularization, PDT, steroids, anti-angiogenesis Albert J AugustinStefan SchollJanna KirchhofDove Medical PressarticleOphthalmologyRE1-994ENClinical Ophthalmology, Vol 2009, Iss default, Pp 175-182 (2009)
institution	DOAJ
collection	DOAJ
language	EN
topic	Ophthalmology RE1-994
spellingShingle	Ophthalmology RE1-994 Albert J Augustin Stefan Scholl Janna Kirchhof Treatment of neovascular age-related macular degeneration: Current therapies
description	Albert J Augustin, Stefan Scholl, Janna KirchhofDepartment of Ophthalmology, Klinikum Karlsruhe, GermanyAbstract: Choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD) is now the leading cause of blindness and severe vision loss among people over the age of 40 in the Western world. Its prevalence is certain to increase substantially as the population ages. Treatments currently available for the disease include laser photocoagulation, verteporfin photodynamic therapy, and intravitreal injections of corticosteroids and anti-angiogenic agents. Many studies have reported the benefits of each of these treatments, although none is without its risks. No intervention actually cures AMD, nor the neovascularization associated with it. However, its symptoms are treated with varying degrees of success. Some treatments stabilize or arrest the progress of the disease. Others have been shown to reverse some of the damage that has already been done. These treatments can even lead to visual improvement. This paper will review the major classes of drugs and therapies designed to treat this condition.Keywords: wet AMD, neovascularization, PDT, steroids, anti-angiogenesis
format	article
author	Albert J Augustin Stefan Scholl Janna Kirchhof
author_facet	Albert J Augustin Stefan Scholl Janna Kirchhof
author_sort	Albert J Augustin
title	Treatment of neovascular age-related macular degeneration: Current therapies
title_short	Treatment of neovascular age-related macular degeneration: Current therapies
title_full	Treatment of neovascular age-related macular degeneration: Current therapies
title_fullStr	Treatment of neovascular age-related macular degeneration: Current therapies
title_full_unstemmed	Treatment of neovascular age-related macular degeneration: Current therapies
title_sort	treatment of neovascular age-related macular degeneration: current therapies
publisher	Dove Medical Press
publishDate	2009
url	https://doaj.org/article/30772ebc671d418aaa9808f2565196a1
work_keys_str_mv	AT albertjaugustin treatmentofneovascularagerelatedmaculardegenerationcurrenttherapies AT stefanscholl treatmentofneovascularagerelatedmaculardegenerationcurrenttherapies AT jannakirchhof treatmentofneovascularagerelatedmaculardegenerationcurrenttherapies
_version_	1718402518457778176

Treatment of neovascular age-related macular degeneration: Current therapies

Ejemplares similares